Your browser doesn't support javascript.
loading
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
Signori, Alessio; Lorscheider, Johannes; Vukusic, Sandra; Trojano, Maria; Iaffaldano, Pietro; Hillert, Jan; Hyde, Robert; Pellegrini, Fabio; Magyari, Melinda; Koch-Henriksen, Nils; Sørensen, Per Soelberg; Spelman, Tim; van der Walt, Anneke; Horakova, Dana; Havrdova, Eva; Girard, Marc; Eichau, Sara; Grand'Maison, Francois; Gerlach, Oliver; Terzi, Murat; Ozakbas, Serkan; Skibina, Olga; Van Pesch, Vincent; Sa, Maria Jose; Prevost, Julie; Alroughani, Raed; McCombe, Pamela A; Gouider, Riadh; Mrabet, Saloua; Castillo-Trivino, Tamara; Zhu, Chao; de Gans, Koen; Sánchez-Menoyo, José Luis; Yamout, Bassem; Khoury, Samia; Sormani, Maria Pia; Kalincik, Tomas; Butzkueven, Helmut.
Afiliação
  • Signori A; Department of Health Sciences, University of Genoa, Genoa, Italy alessio.signori@medicina.unige.it.
  • Lorscheider J; Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Vukusic S; Service de Neurologie A, Hopital Neurologique, Hospices Civils de Lyon, Lyon Bron, France.
  • Trojano M; Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
  • Iaffaldano P; Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
  • Hillert J; Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • Hyde R; Biogen International, Zurich, Switzerland.
  • Pellegrini F; Biogen International, Zurich, Switzerland.
  • Magyari M; Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen, Denmark.
  • Koch-Henriksen N; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
  • Sørensen PS; Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen, Denmark.
  • Spelman T; Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • van der Walt A; Department of Neurology, Box Hill Hospital, Melbourne, Victoria, Australia.
  • Horakova D; Monash University Central Clinical School, Melbourne, Victoria, Australia.
  • Havrdova E; Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Girard M; Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
  • Eichau S; CHUM and Universite de Montreal, Montreal, Quebec, Canada.
  • Grand'Maison F; Neurology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Gerlach O; Neuro Rive-Sud, Quebec, Quebec, Canada.
  • Terzi M; Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
  • Ozakbas S; School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
  • Skibina O; Ondokuz Mayis Üniversitesi, Samsun, Turkey.
  • Van Pesch V; Dokuz Eylul University, Izmir, Turkey.
  • Sa MJ; Neurology, Box Hill Hospital, Melbourne, Victoria, Australia.
  • Prevost J; Department of Neuroscience, Monash University Central Clinical School, Melbourne, Victoria, Australia.
  • Alroughani R; Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • McCombe PA; Neurology, Centro Hospitalar de São João, Porto, Portugal.
  • Gouider R; Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal.
  • Mrabet S; Centre integre de sante et de services sociaux des Laurentides point de service de Saint-Jerome, Saint-Jerome, Quebec, Canada.
  • Castillo-Trivino T; Amiri Hospital, Kuwait City, Kuwait.
  • Zhu C; UQCCR, The University of Queensland, Brisbane, Queensland, Australia.
  • de Gans K; Department of Neurology, Razi Hospital, Manouba, Tunisia.
  • Sánchez-Menoyo JL; Department of Neurology, Razi University Hospital, Manouba, Tunisia.
  • Yamout B; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
  • Khoury S; Neurology, Donostia University Hospital, San Sebastian, Spain.
  • Sormani MP; Neuroscience, Centre Clinical School, Monash University, Victoria, Australia.
  • Kalincik T; Groene Hart Ziekenhuis, Gouda, The Netherlands.
  • Butzkueven H; Neurology, Galdakao Hospital, Vizcaya, Spain.
J Neurol Neurosurg Psychiatry ; 94(1): 23-30, 2023 01.
Article em En | MEDLINE | ID: mdl-36171104
ABSTRACT

BACKGROUND:

Over the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on long-term disability trajectories was demonstrated. The aim of this study was to identify subgroups of patients with SPMS with similar longitudinal trajectories of disability over time.

METHODS:

All patients with MS collected within Big MS registries who received an SPMS diagnosis from physicians (cohort 1) or satisfied the Lorscheider criteria (cohort 2) were considered. Longitudinal Expanded Disability Status Scale (EDSS) scores were modelled by a latent class growth analysis (LCGA), using a non-linear function of time from the first EDSS visit in the range 3-4.

RESULTS:

A total of 3613 patients with SPMS were included in the cohort 1. LCGA detected three different subgroups of patients with a mild (n=1297; 35.9%), a moderate (n=1936; 53.6%) and a severe (n=380; 10.5%) disability trajectory. Median time to EDSS 6 was 12.1, 5.0 and 1.7 years, for the three groups, respectively; the probability to reach EDSS 6 at 8 years was 14.4%, 78.4% and 98.3%, respectively. Similar results were found among 7613 patients satisfying the Lorscheider criteria.

CONCLUSIONS:

Contrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pessoas com Deficiência / Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pessoas com Deficiência / Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália